CGI Complete

CGI's Complete™ Program

Cancer Genetics' Complete™ offering is a unique suite of common and proprietary tests that assists clinicians in determining the best treatment options to improve patient outcomes. Each program integrates the latest diagnostic and prognostic biomarkers across multiple methodologies. CGI offers Complete™ testing for a number of hematological neoplasms and solid tumor cancers, including CLL/SLL, DLBCL, MCL, MPN, colorectal, lung, and breast cancers.

CGI’s Complete Testing for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS) represent a group of diseases of the blood and bone marrow characterized by ineffective hematopoiesis and peripheral blood cell cytopenias. Over 60,000 people in the US are living with a history of MDS. The major clinical concerns associated with MDS include the high prevelance of comorbidities caused by cytopenias and the risk of progression to acute myeloid leukemia (AML). Today, morphology and cytogenetics play an important role in diagnosis, risk stratification, and prognostication. Recent discoveries of recurrent gene regions containing molecular mutations associated with MDS, have shown to help greatly improve upon traditional risk stratification methods, of which, molecular testing is absent.

By offering the most comprehensive testing panel available, CGI’s MDS Complete™ Program can help in determining the best personalized course of action for the patient.


MDS Complete™

Physicians can order tests individually or allow CGI directors to perform a panel evaluation as determined necessary.

MDS Complete Work Flow 050715

This work up is intended as a guide for the comprehensive suite of diagnostic tests included in MDS Complete™ to diagnose and monitor MDS. Physicians can order tests individually or allow CGI pathologists and directors to determine a panel evaluation as determined necessary.

Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT1-2 days
The lymphoid panel determines expression levels of cell surface antigens by flow cytometry that provide diagnostic information for the diagnosis and for monitoring therapy. This panel includes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD71, CD117, HLA-DR, sKappa, sLambda.
MethodologyFlow cytometry
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of leukemia and lymphoma and for post-treatment follow-up.
CPT Codes88184; 88185 (x17); 88189
TAT1-2 days
Designed for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN), Focus::Myeloid™ is a unique NGS panel with 54 biomarkers that provides actionable information for improved diagnosis, prognosis, and risk stratification.
MethodologyNext Generation Sequencing
Analytical Sensitivity5%
Specimen RequirementsOne Lavender (EDTA) tube of peripheral blood or bone marrow aspirate. Minimum: 2-3 mL. Shipped at room temperature.
Clinical IndicationsFor the diagnosis, prognosis, and risk stratification of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloproliferative Neoplasms (MPN)
CPT Codes81455
TAT10-14 days
MethodologyG-banding
Specimen Requirements1 Green/NaHeparin tube (3-5 ml) peripheral blood or bone marrow at room temp.
CPT Codes88237; 88262; 88280; 88291
TAT5-7 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis, prognosis, monitoring of response to therapy or progression of disease of myelodysplastic syndrome (MDS).
CPT Codes88271(8); 88275(4); 88291
TAT3-5 days